Type 1 Diabetes TrialNet Clinical Network Hub

1 型糖尿病 TrialNet 临床网络中心

• 批准号: 10700788
• 负责人: CARLA J GREENBAUM
• 金额: $ 100万
• 依托单位: BENAROYA RESEARCH INST AT VIRGINIA MASON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-31 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10700788
• 关键词: Antibodies; Area; Australia; Autoantibodies; Canada; Clinical; Clinical Trials; Communication; Conduct Clinical Trials; Data; Development; Diabetes Mellitus; Disease; Disease Progression; Enrollment; Finland; Germany; Goals; Grant; Individual; Information Dissemination; Insulin-Dependent Diabetes Mellitus; International; Italy; Mission; Monitor; Natural History; Participant; Phase I Clinical Trials; Prevention; Process; Research Personnel; Risk; Site; Sweden; Thinking; Time; clinical center; clinical diagnosis; innovation; insulin dependent diabetes mellitus onset; member; prevent; recruit; screening; success

PROJECT SUMMARY / ABSTRACT TrialNet's mission is to bring disease modifying therapy to clinical use in type 1 diabetes (T1D) with a primary focus on conducting clinical trials at early stages of disease to prevent or delay clinical onset. TrialNet is an international consortium of twenty-five Clinical Centers and hundreds of Affiliate sites in US, Canada, UK, Sweden, Finland, Germany, Italy, and Australia. These sites together with the TrialNet Coordinating Center (TNCC), the TrialNet Clinical Hub (HUB), and members of our Collaborative Mechanistic Studies Panel (CMSP), (a) conduct natural history studies to describe the progression of T1D and identify individuals for clinical trials, (b) conduct clinical trials of disease modifying therapy both prior to and after clinical diagnosis, and (c) increase the scientific value of trials through mechanistic studies involving investigators within and external to TrialNet. The mission of the Type 1 Diabetes TrialNet Hub is to increase the efficiency of critical Network activities by supporting collaborative and innovative approaches for screening, recruitment, retention, trial development and implementation, and dissemination of results. With considerable success during the previous grant period, this application describes our proposal to continue to serve as the Diabetes TrialNet Clinical HUB. We focus on three areas; activities to (a) enhance risk screening to identify at-risk individuals, (b) enhance enrollment and retention in clinical trials, and (c) enhance clinical administration to effectively implement TrialNet's goals.

项目摘要/摘要

项目成果

TCF7L2 Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes.

TCF7L2 遗传变异不会影响有 1 型糖尿病风险的自身抗体阳性个体的胰岛素敏感性或分泌指数。

• DOI: 10.2337/dc21-0531
• 发表时间: 2021
• 期刊: Diabetes care
• 影响因子: 16.2
• 作者: Redondo,MariaJ;Warnock,MeganV;Libman,IngridM;Bocchino,LauraE;Cuthbertson,David;Geyer,Susan;Pugliese,Alberto;Steck,AndreaK;Evans-Molina,Carmella;Becker,Dorothy;Sosenko,JayM;Bacha,Fida;Type1DiabetesTrialNetStudyGroup
• 通讯作者: Type1DiabetesTrialNetStudyGroup

Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals.

自身抗体逆转：改变多重自身抗体阳性个体的风险类别。

• DOI: 10.2337/dc19-1731
• 发表时间: 2020
• 期刊: Diabetes care
• 影响因子: 16.2
• 作者: So,Michelle;O'Rourke,Colin;Bahnson,HenryT;Greenbaum,CarlaJ;Speake,Cate
• 通讯作者: Speake,Cate

Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. Diabetes Care 2020;43:913-917.

对 So 等人的评论的回应

• DOI: 10.2337/dci20-0016
• 发表时间: 2020
• 期刊: Diabetes care
• 影响因子: 16.2
• 作者: So,Michelle;O'Rourke,Colin;Bahnson,HenryT;Greenbaum,CarlaJ;Speake,Cate
• 通讯作者: Speake,Cate

Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes.

胰岛素是必要的但还不够：改变 1 型糖尿病的治疗模式。

• DOI: 10.12688/f1000research.21801.1
• 发表时间: 2020
• 期刊: F1000Research
• 作者: Lord,Sandra;Greenbaum,CarlaJ
• 通讯作者: Greenbaum,CarlaJ

Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes.

• DOI: 10.1007/s00125-017-4294-3
• 发表时间: 2017-08
• 期刊: Diabetologia
• 影响因子: 8.2
• 作者: Snowhite IV;Allende G;Sosenko J;Pastori RL;Messinger Cayetano S;Pugliese A
• 通讯作者: Pugliese A